A top-tier biopharmaceutical company was interested in incorporating an Artificial Intelligence (AI)-based model that predicts treatment response to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) using baseline chest CT scans.
Identifying patients more likely to respond to their therapy may improve the design of future clinical studies by maximizing the efficacy of the treatment arm in a specific disease phenotype. In a post-approval scenario, the predictive algorithm would also be useful as a companion diagnostic (CDx) to treat patients likely to benefit from the treatment.
As pay-for-performance reimbursement models grow in the immunotherapy space, it is more important than ever for practitioners to administer the right treatment for the right patient at the right time.
A large database of more than 1000 chest CT scans from a failed phase-III study was used to extract insights applicable to future studies. The dataset included information about patient outcomes such as treatment response and overall survival. The biopharmaceutical partner engaged in a value-based strategic collaboration with Quibim to design and create an AI model that could predict treatment response based on pre-treatment CT scans.
Quibim performed a feasibility analysis and found a high variability in the image quality across the 70+ sites involved in the study. All images meeting minimum quality requirements were transformed into a standard image quality by GAN-based image harmonization algorithms implemented by Quibim.
After the image quality harmonization of the entire dataset, Quibim developed and validated an AI algorithm based on radiomics, deep features, and deep learning techniques. The resulting algorithm correctly predicted whether or not the patient will respond to immunotherapy in 80 per cent of cases.
What’s in it for the biopharmaceutical partner and Quibim?
Read more
Read more
Read more
